XLO
Xilio Therapeutics, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Buy
+26/100
Last price
8.97
▼ 0.14 (1.54%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
9.57
Prev close
9.11
Day high
9.32
Day low
8.81
Volume
6.14K
Market cap
$59.22M
P/E (TTM)
—
52W range
6.47 – 12.59
Day trading desk
Gap from prior close
+5.02%
Prior close 9.11
VWAP
9.00
-0.30% from price
Relative volume
0.27×
Quiet session
Session range
8.60%
8.81 – 9.57
Position in range
21%
Near session low
ATR (14D)
0.32
3.60% of price
Prior day high
9.49
PDH
Prior day low
9.07
PDL
Bid / ask spread
—
Quote not published
Session volume
6.14K
Avg 22.98K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+0.69%
-1.3%
1M
0.00%
-1.2%
3M
-3.02%
-7.5%
6M
+5.88%
-12.3%
YTD
+0.45%
-13.8%
1Y
-21.41%
-37.8%
3Y
-69.53%
-151.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on XLO open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+2.73M
Net buying
Buy transactions
2
2.73M shares
Sell transactions
2
5.24K shares
Net transactions
+4
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
1.71M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Mar 26, 26 | SHANNON JAMES SAMUEL Director |
BUY | 5.00K | $43.95K | Direct |
| Jan 2, 26 | BRENNAN KEVIN M Officer |
SELL | 1.83K | $1.17K | Direct |
| Jan 2, 26 | FRANKENFIELD CHRISTOPHER JAMES Chief Financial Officer |
SELL | 7.03K | $4.52K | Direct |
| Dec 31, 25 | RUSSO RENE PHARM.D. Chief Executive Officer |
— | 44.25K | — | Direct |
| Dec 31, 25 | BRENNAN KEVIN M Officer |
— | 5.00K | — | Direct |
| Dec 31, 25 | FRANKENFIELD CHRISTOPHER JAMES Chief Financial Officer |
— | 19.38K | — | Direct |
| Dec 31, 25 | LUPTAKOVA KATARINA M.D. Officer |
— | 16.63K | — | Direct |
| Nov 26, 25 | GILEAD SCIENCES INC Beneficial Owner of more than 10% of a Class of Security |
CONVERSION | 13.34M | $10.00M | Direct |
| Jun 17, 25 | SHANNON JAMES SAMUEL Director |
BUY | 70.00K | $48.09K | Direct |
| Jun 16, 25 | RUSSO RENE PHARM.D. Chief Executive Officer |
BUY | 36.29K | $24.68K | Direct |
| Jan 2, 25 | BRENNAN KEVIN M Officer |
SELL | 1.80K | $1.77K | Direct |
| Jan 2, 25 | FRANKENFIELD CHRISTOPHER JAMES Chief Financial Officer |
SELL | 6.95K | $6.84K | Direct |
| Dec 31, 24 | RUSSO RENE PHARM.D. Chief Executive Officer |
— | 44.25K | — | Direct |
| Dec 31, 24 | RUSSO RENE PHARM.D. Chief Executive Officer |
— | 44.25K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BRENNAN KEVIN M |
Officer | 6.37K | Sale |
FRANKENFIELD CHRISTOPHER JAMES |
Chief Financial Officer | 24.77K | Sale |
GILEAD SCIENCES INC |
Beneficial Owner of more than 10% of a Class of Security | 0 | Conversion of Exercise of derivative security |
LUPTAKOVA KATARINA M.D. |
Officer | 33.25K | Conversion of Exercise of derivative security |
RUSSO RENE PHARM.D. |
Chief Executive Officer | 325.42K | Conversion of Exercise of derivative security |
SHANNON JAMES SAMUEL |
Director | 10.00K | Purchase |
Fundamentals
Market cap$59.22M
Enterprise value$-70.52M
Revenue (TTM)$64.09M
Gross profit$53.30M
EBITDA$-30.03M
Net income$-21.83M
EPS (TTM)$-0.60
Free cash flow$-37.56M
Total cash$136.04M
Total debt$6.30M
Book value / share$10.98
Shares outstanding6.58M
Float3.40M
Short % of float7.01%
Dividend yield0.00%
Beta (5Y)-0.12
Valuation & profitability ratios
Trailing P/E—
Forward P/E-15.52
PEG ratio—
Price / sales—
Price / book0.82
EV / revenue-1.10
EV / EBITDA2.35
Gross margin83.16%
Operating margin-18.68%
Profit margin-34.06%
Return on equity-55.03%
Return on assets-13.61%
Debt / equity8.72
Current ratio4.25
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $43.77M | $6.34M | $0 | $0 | +589.9% |
| Operating revenue | $43.77M | $6.34M | $0 | $0 | +589.9% |
| Research & development | $56.04M | $41.21M | $52.14M | $59.20M | +36.0% |
| Selling, general & admin | $29.71M | $24.78M | $27.00M | $29.95M | +19.9% |
| Total operating expense | $85.75M | $65.99M | $79.13M | $89.15M | +29.9% |
| Operating income | -$41.98M | -$59.65M | -$79.13M | -$89.15M | +29.6% |
| Pre-tax income | -$35.04M | -$58.24M | -$76.40M | -$88.22M | +39.8% |
| Net income | -$35.04M | -$58.24M | -$76.40M | -$88.22M | +39.8% |
| Net income to common | -$35.04M | -$58.24M | -$76.40M | -$88.22M | +39.8% |
| Basic EPS | -4.19 | -15.26 | -38.92 | -45.08 | +72.5% |
| Diluted EPS | -4.19 | -15.26 | -38.92 | -45.08 | +72.5% |
| EBIT | -$41.98M | -$59.65M | -$79.13M | -$89.15M | +29.6% |
| EBITDA | -$40.44M | -$58.00M | -$77.23M | -$87.30M | +30.3% |
| Basic shares | 8.36M | 3.82M | 1.96M | 1.96M | +118.7% |
| Diluted shares | 8.36M | 3.82M | 1.96M | 1.96M | +118.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $137.53M | $55.29M | $44.70M | $120.39M | — | +148.7% |
| Cash & short-term investments | $137.53M | $55.29M | $44.70M | $120.39M | — | +148.7% |
| Total current assets | $145.03M | $60.23M | $48.13M | $124.50M | — | +140.8% |
| Property, plant & equipment | $7.85M | $9.06M | $11.07M | $12.84M | — | -13.3% |
| Total assets | $154.69M | $71.08M | $60.93M | $139.16M | — | +117.6% |
| Total current liabilities | $56.27M | $27.26M | $15.96M | $21.12M | — | +106.4% |
| Current debt | — | — | $3.31M | $6.67M | — | — |
| Long-term debt | — | — | — | $3.17M | $9.63M | — |
| Total debt | $6.95M | $8.14M | $12.50M | $19.94M | — | -14.6% |
| Total liabilities | $119.41M | $53.48M | $24.10M | $33.52M | — | +123.3% |
| Retained earnings | -$418.79M | -$383.75M | -$325.51M | -$249.11M | — | -9.1% |
| Shareholder equity | $35.27M | $17.60M | $36.83M | $105.65M | — | +100.4% |
| Working capital | $88.75M | $32.97M | $32.17M | $103.38M | — | +169.2% |
| Net tangible assets | $35.27M | $17.60M | $36.83M | $105.65M | — | +100.4% |
| Shares issued | 4.53M | 3.27M | 1.97M | 1.96M | — | +38.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$35.04M | -$58.24M | -$76.40M | -$88.22M | +39.8% |
| Depreciation & amortisation | $1.54M | $1.64M | $1.90M | $1.85M | -6.3% |
| Stock-based compensation | $6.94M | $6.43M | $7.38M | $8.42M | +7.8% |
| Change in working capital | $25.13M | $31.78M | -$1.66M | $2.00M | -20.9% |
| Operating cash flow | -$4.99M | -$18.38M | -$68.62M | -$75.72M | +72.8% |
| Capital expenditure | -$518.00K | -$36.00K | -$486.00K | -$1.87M | -1,338.9% |
| Investing cash flow | -$518.00K | -$36.00K | -$486.00K | -$1.87M | -1,338.9% |
| Financing cash flow | $87.78M | $29.20M | -$6.55M | -$69.00K | +200.6% |
| Free cash flow | -$5.51M | -$18.41M | -$69.11M | -$77.59M | +70.1% |
| End cash position | $139.34M | $57.07M | $46.29M | $121.95M | +144.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $18.69M | $12.65M | $13.69M | $19.07M | $8.08M | +47.8% |
| Operating revenue | $18.69M | $12.65M | $13.69M | $19.07M | $8.08M | +47.8% |
| Research & development | $14.56M | $19.83M | $18.12M | $14.32M | $15.33M | -26.6% |
| Selling, general & admin | $7.62M | $6.93M | $7.40M | $6.67M | $7.12M | +10.0% |
| Total operating expense | $22.18M | $26.76M | $25.52M | $21.00M | $22.45M | -17.1% |
| Operating income | -$3.49M | -$14.11M | -$11.84M | -$1.93M | -$14.37M | +75.3% |
| Pre-tax income | -$6.37M | -$9.53M | $10.36M | -$16.29M | -$15.84M | +33.1% |
| Net income | -$6.37M | -$9.53M | $10.36M | -$16.29M | -$15.84M | +33.1% |
| Net income to common | -$6.37M | -$9.53M | $10.36M | -$16.29M | -$15.84M | +33.1% |
| Basic EPS | -0.33 | -0.58 | 0.96 | -1.54 | -2.30 | +43.1% |
| Diluted EPS | -0.33 | -0.58 | 0.81 | -1.54 | -2.30 | +43.1% |
| EBIT | -$3.49M | -$14.11M | -$11.84M | -$1.93M | -$14.37M | +75.3% |
| EBITDA | -$3.16M | -$13.77M | -$11.51M | -$1.59M | -$13.98M | +77.0% |
| Basic shares | 19.40M | 5.78M | 10.84M | 10.29M | 6.89M | +235.6% |
| Diluted shares | 19.40M | 5.78M | 12.83M | 10.29M | 6.89M | +235.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $136.04M | $150.33M | $137.53M | $103.76M | $121.55M | -9.5% |
| Cash & short-term investments | $136.04M | $150.33M | $137.53M | $103.76M | $121.55M | -9.5% |
| Total current assets | $145.47M | $154.21M | $145.03M | $124.09M | $123.72M | -5.7% |
| Property, plant & equipment | $6.97M | $7.47M | $7.85M | $7.80M | $8.30M | -6.7% |
| Total assets | $154.25M | $163.49M | $154.69M | $133.69M | $133.81M | -5.6% |
| Total current liabilities | $34.20M | $42.96M | $56.27M | $56.40M | $53.26M | -20.4% |
| Total debt | $6.30M | $6.64M | $6.95M | $7.26M | $7.57M | -5.0% |
| Total liabilities | $81.99M | $90.94M | $119.41M | $141.79M | $126.74M | -9.8% |
| Retained earnings | -$434.69M | -$428.32M | -$418.79M | -$429.15M | -$412.86M | -1.5% |
| Shareholder equity | $72.26M | $72.54M | $35.27M | -$8.10M | $7.07M | -0.4% |
| Working capital | $111.27M | $111.25M | $88.75M | $67.69M | $70.46M | +0.0% |
| Net tangible assets | $72.26M | $72.54M | $35.27M | -$8.10M | $7.07M | -0.4% |
| Shares issued | 6.58M | 5.78M | 4.53M | 3.70M | 3.70M | +13.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$6.37M | -$9.53M | $10.36M | -$16.29M | -$15.84M | — | +33.1% |
| Depreciation & amortisation | $331.00K | $344.00K | $323.00K | $340.00K | $381.00K | — | -3.8% |
| Stock-based compensation | $1.60M | $2.21M | $2.93M | $1.12M | $1.35M | — | -27.7% |
| Change in working capital | -$18.26M | -$12.07M | $5.66M | -$18.05M | -$2.70M | — | -51.3% |
| Operating cash flow | -$18.76M | -$22.34M | -$2.00M | -$17.50M | -$14.48M | — | +16.0% |
| Capital expenditure | -$19.00K | -$556.00K | -$95.00K | — | -$401.00K | -$22.00K | +96.6% |
| Investing cash flow | -$19.00K | -$556.00K | -$95.00K | $0 | -$401.00K | — | +96.6% |
| Financing cash flow | $4.49M | $35.71M | $35.87M | -$285.00K | $47.36M | — | -87.4% |
| Free cash flow | -$18.78M | -$22.90M | -$2.09M | -$17.50M | -$14.88M | — | +18.0% |
| End cash position | $137.86M | $152.15M | $139.34M | $105.56M | $123.34M | — | -9.4% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.59 | -0.33 | +44.1% |
| Mar 2026 | -0.66 | — | — |
| Sep 2025 | -0.42 | -1.54 | -266.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.82 | 1 | $4.84M | -74.6% |
| Next quarter | -0.85 | 1 | $4.15M | — |
| Current year | -2.59 | 1 | $40.33M | -7.9% |
| Next year | -2.23 | 1 | $26.53M | -34.2% |
Analyst targets & ownership
Mean target$20.00
High target$20.00
Low target$20.00
Implied upside122.97%
Analyst count1
ConsensusNONE
Strong buy / Buy0 / 1
Hold0
Sell / Strong sell0 / 0
Held by insiders25.98%
Held by institutions50.16%
Institutions holding32
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
9.00
-0.39% from price
SMA 20
9.00
-0.03% from price
SMA 50
9.07
-0.79% from price
SMA 100
8.86
+1.25% from price
SMA 200
8.58
+4.93% from price
EMA 12
9.01
-0.48% from price
EMA 26
9.02
-0.51% from price
EMA 50
8.99
-0.24% from price
RSI (14)
49.2
Neutral
MACD (12,26,9)
-0.00
Hist 0.01
ATR (14)
0.32
3.59% of price
Realised vol 30D
14.3%
Annualised
Bollinger upper
9.12
20, 2σ
Bollinger lower
8.88
20, 2σ
50 / 200 cross
Golden
9.07 vs 8.58
Trend bias
Above 200
+4.93%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.89
Less volatile than market
Correlation to SPY
0.26
Largely independent
Realised vol 30D
14.3%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-40.0%
Peak to trough
Max drawdown 5Y
-98.0%
Peak to trough
ATR 14
0.32
3.59% of price
Beta (reported)
-0.12
5Y monthly, from filing
Short interest
Shares short
412.96K
Prior 421.92K
Change vs prior
-2.1%
Shorts covering
% of float
7.01%
Normal
% of shares out
6.28%
Against total outstanding
Days to cover
37.0
Crowded exit
Float
3.40M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 6, 25 | Leerink Partners | INITIATED | — | Outperform |
| Nov 8, 24 | Raymond James | MAINTAINED | Outperform | Outperform |
| May 30, 23 | Chardan Capital | MAINTAINED | Buy | Buy |
| May 11, 23 | Chardan Capital | MAINTAINED | — | Buy |
| Jan 27, 23 | Morgan Stanley | MAINTAINED | — | Overweight |
| Dec 21, 22 | Chardan Capital | INITIATED | — | Buy |
| Nov 10, 22 | Raymond James | MAINTAINED | — | Outperform |
| Aug 10, 22 | Morgan Stanley | MAINTAINED | — | Overweight |
| Jan 10, 22 | HC Wainwright & Co. | INITIATED | — | Buy |
| Nov 16, 21 | Raymond James | INITIATED | — | Outperform |
| Nov 16, 21 | Cowen & Co. | INITIATED | — | Outperform |
| Nov 16, 21 | Morgan Stanley | INITIATED | — | Overweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:14
Split dateMar 16, 2026
SEC filings
Periodic Financial Reports
10-Q · 2026-08-12
Corporate Changes & Voting Matters
8-K · 2026-06-12
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-05-27
Corporate Changes & Voting Matters
8-K · 2026-05-12
Proxy Statements
DEF 14A · 2026-04-28
Corporate Changes & Voting Matters
8-K · 2026-04-16
Corporate Changes & Voting Matters
8-K · 2026-03-23
Corporate Changes & Voting Matters
8-K · 2026-03-12
Headlines
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 4d ago
Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer
GlobeNewswire · 9d ago
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 34d ago
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
GlobeNewswire · 56d ago
3 Small-Cap Biotech Stocks Pairing Rapid Revenue Growth With High Insider Ownership
Simply Wall St. · 75d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.